Understanding the relationship between sweat chloride and lung function in cystic fibrosis

Chest

Volumn 144, Issue 4, 2013, Pages 1418-

  Heltshe, Sonya L ^a,c   Mayer Hamblett, Nicole ^a,b,c   Rowe, Steven M ^d  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Seattle Children's Research Institute   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; IVACAFTOR;

CORRELATION ANALYSIS; CYSTIC FIBROSIS; ENZYME ACTIVITY; FORCED EXPIRATORY VOLUME; HUMAN; LETTER; LUNG FUNCTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SWEAT TEST; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84885117570     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.13-1320     Document Type: Letter

References (3)

1. Durmowicz AG, Witzmann KA, Rosebraugh CJ, Chowdhury BA. Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience. Chest. 2013; 143 (1): 14-18.
2. Farrell PM, Rosenstein BJ, White TB, et al; Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008; 153 (2): S4-S14.
3. Seliger VI, Rodman D, Van Goor F, Schmelz A, Mueller P. The predictive potential of the sweat chloride test in cystic fibrosis patients with the G551D mutation [published online ahead of print April 26, 2013]. J Cyst Fibros. doi: 10.1016/j.jcf.2013.03.004.